Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
Authors:
- F. KockFKF. Kock
- 1 June 1998
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 17 (6) , 447-453
Abstract
Once-daily trovafloxacin 200 mg was compared with high-dose amoxicillin, 1 g three times daily, given for 7 to 10 days. At end of treatment (day 10), the response was clinically successful (cure + improvement) in 93% of 152 clinically evaluable trovafloxacin patients and in 89% of 160 amoxicillin patients. At study end (day 35), respective rates were 91% and 81% (95% confidence interval: 1.6, 17.6; P=0.01). In evaluable patients with positive baseline radiographs, 93% of trovafloxacin and 88% of amoxicillin patients demonstrated radiological resolution at end of treatment.Streptococcus pneumoniae andHaemophilus influenzae eradication rates were comparable at end of treatment in both treatment groups, but at study endStreptococcus pneumoniae eradication rates were higher in trovafloxacin patients (100% vs 81%). At study end, all four trovafloxacin patients with baseline penicillinresistantStreptococcus pneumoniae were clinically cured with pathogen eradication, whereas two of five amoxicillin patients with baseline penicillin-resistantStreptococcus pneumoniae were clinical failures with pathogen persistence. For patients in whom no pathogen was identified, trovafloxacin was significantly more effective at end of treatment (P=0.096) and study end (P=0.013). Treatment-related adverse events were comparable; the most common were headache, vomiting and dizziness in trovafloxacin patients, and diarrhoea, headache and abdominal pain in amoxicillin patients.Keywords
This publication has 29 references indexed in Scilit:
- Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issueEuropean Respiratory Journal, 1995
- In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and-resistant Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 1995
- Quinolone Activity against AnaerobesDrugs, 1995
- In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobialDiagnostic Microbiology and Infectious Disease, 1994
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- Antibacterial Therapy for Lower Respiratory Tract Infections in Adults: A ReviewClinical Infectious Diseases, 1992
- The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unitRespiratory Medicine, 1992
- New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for TherapyMedicine, 1990